AKT1 and neoplasm: The PI3K/Akt pathway, which is frequently activated in various cancers, including glioblastoma, where it plays a key role in tumor survival and resistance to treatment [16], could interact with ERK1/2 signaling to amplify the therapeutic effects of MC4R inhibition.